Friday, November 14, 2014

Another rising star! BLINATUMOMAB

Should we use this for Burkitt lymphoma?
It is normally reviewed for Philadelphia negative ALL...involving the T-cell...

"Blinatumomab received the FDA's Breakthrough Therapy designation earlier this year (OT 8/10/14 issue), which was enacted as part of the FDA's 2012 Safety and Innovation Act to expedite the development and review time of a potential new drug for serious or life-threatening disease where early clinical evidence suggests the drug may demonstrate substantial improvement compared with existing therapies." From Oncology Times
Post a Comment